Thermo Fisher Projects 7% Annual Organic Revenue Growth, Low-Teens EPS Growth Long-Term
TMO sits 17% above its 52-week low of $385.46.
Summary
Thermo Fisher Scientific announced its long-term financial outlook, projecting 7% annual organic revenue growth and low-teens adjusted earnings-per-share growth. This new guidance, provided during the company's investor day, reflects management's confidence in improving market demand trends and the strategic impact of AI on scientific advancements. For a company of Thermo Fisher's size, these specific long-term targets are material and will likely be incorporated into analyst models, influencing long-term valuation and investor sentiment. Investors will be closely watching for further details from the investor day presentation regarding the strategies to achieve these ambitious growth targets.
At the time of this announcement, TMO was trading at $450.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $166.4B. The 52-week trading range was $385.46 to $643.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.